US Bancorp DE Decreases Stake in Fresenius Medical Care AG & Co. KGaA $FMS

US Bancorp DE cut its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 38.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,255 shares of the company’s stock after selling 29,405 shares during the quarter. US Bancorp DE’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $1,218,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $36,000. Atlantic Union Bankshares Corp purchased a new position in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at approximately $43,000. Hantz Financial Services Inc. raised its holdings in Fresenius Medical Care AG & Co. KGaA by 568.5% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after acquiring an additional 1,768 shares during the period. Huntington National Bank lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% during the second quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after acquiring an additional 1,618 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth $73,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $23.03 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46. The company has a market capitalization of $13.35 billion, a P/E ratio of 12.06, a P/E/G ratio of 0.68 and a beta of 0.91. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92. The firm’s 50 day simple moving average is $23.24 and its 200 day simple moving average is $24.40.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $4.80 billion. Sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

FMS has been the topic of a number of analyst reports. Jefferies Financial Group lowered Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research note on Tuesday, February 24th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Finally, Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.